Compound ID | 151
Class: Beta-lactam
| Agent Type: | Semisynthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Target Pathogen: | Active against multidrug resistant Gram-negative infections |
| Propensity to select resistant mutants: | No (demonstrated high resistance) |
| Description: | A siderophore-sulfactam |
| Institute where first reported: | Basilea Pharmaceutica, Switzerland |
| Year first mentioned: | 2008 |
| Highest development stage: | Phase 1 |
| Development status: | Withdrawn |
| Reason dropped: | Liver injury detected 3-days post treatment (iv formulation); preclinical studies of inhalation also terminated due to 'lack of confidence in candidate's success' |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/52942440 |
| Guide to Pharmacology: | BAL30072 |
| Citations: |
|